title: Predictive and Prognostic Value of the TauProtein in Breast Cancer.
abstract: OBJECTIVE
  Predictive markers for response to chemotherapy are required in breast cancer. The Tau protein is a microtubule-associated protein variably expressed in breast cancer. The objective of our study was to describe drug resistance induced by the tau protein, and its predictive and prognostic value in breast cancer.
  
  
  METHODS
  Medline and PubMed databases were searched in April 2015 for terms "tau protein", "breast cancer", "chemotherapy sensitivity", "biomarker" and "taxane resistance".
  
  
  RESULTS
  In vitro, tau protein competes with taxane for controlling microtubule dynamic and loss of tau expression may render microtubules more vulnerable to the effects of taxanes. High tau protein expression was associated with better prognosis, even after adjustment for grade, hormone receptor and human epidermal growth factor receptor-2 expression, nodal status. The predictive value of the tau protein for sensitivity to taxane is discordant despite there being a trend for an association between low tau expression and increased response rate.
  
  
  CONCLUSIONS
  Tau protein expression is insufficient for identifying a subset of patients with carcinomas that may benefit more from chemotherapy.
authors.affiliation: Department of Breast and Gynaecological Surgery, Curie Institute, Versailles-St-Quentin-en-Yvelines University, Versailles, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Bonneau
authors.affiliation: UMR3664: "Dynamic of the cell nucleus" Unit, National Center for scientific Research (CNRS), Curie Institute, Paris, France.
authors.forename: Zachary A
authors.initials: ZA
authors.lastname: Gurard-Levin
authors.affiliation: UMR 981: "Predictive biomarkers and new molecular therapeutic strategies in cancer", Integrated Research Cancer Institute in Villejuif, Paris, France.
authors.forename: Fabrice
authors.initials: F
authors.lastname: Andre
authors.affiliation: Yale Cancer Center Genetics and Genomics Program, Yale School of Medicine, New Haven, CT, U.S.A.
authors.forename: Lajos
authors.initials: L
authors.lastname: Pusztai
authors.affiliation: Department of Breast and Gynaecological Surgery, Curie Institute, Versailles-St-Quentin-en-Yvelines University, Versailles, France EA 7285: "Clinics risks and security in women's health and perinatal health", Versailles-St-Quentin-en-Yvelines University, Versailles, France roman.rouzier@curie.fr.
authors.forename: Roman
authors.initials: R
authors.lastname: Rouzier
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D011379:Prognosis; D043823:Taxoids / Q000627:therapeutic use*; D016875:tau Proteins / Q000235:genetics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D001952:Bridged-Ring Compounds; C054369:MAPT protein, human; D043823:Taxoids; D016875:tau Proteins; C080625:taxane
keywords: Microtubule-associated protein; breast cancer; cancer treatment; chemotherapy sensitivity; review; tau protein; taxanes